Imidazo[2,1-b]benzothiazole-7-carboxamide, 2-[4-(1-aminocyclopropyl)phenyl]-N-[3-(1-piperidinyl)propyl]- manufacturers
|
| | Imidazo[2,1-b]benzothiazole-7-carboxamide, 2-[4-(1-aminocyclopropyl)phenyl]-N-[3-(1-piperidinyl)propyl]- Basic information |
| | Imidazo[2,1-b]benzothiazole-7-carboxamide, 2-[4-(1-aminocyclopropyl)phenyl]-N-[3-(1-piperidinyl)propyl]- Chemical Properties |
| density | 1.39±0.1 g/cm3(Predicted) | | pka | 13.65±0.46(Predicted) |
| | Imidazo[2,1-b]benzothiazole-7-carboxamide, 2-[4-(1-aminocyclopropyl)phenyl]-N-[3-(1-piperidinyl)propyl]- Usage And Synthesis |
| Uses | c-Myc inhibitor 9 (compound 332) is a c-Myc inhibitor with an logEC50 of ≥6. c-Myc inhibitor 9 inhibits tumor growth in nude mouse models. c-Myc inhibitor 9 can be used for cancer research[1]. | | in vivo | c-Myc inhibitor 9 (3 mg/kg; i.p., twice a week for 49 days) effectively inhibits tumor growth in nude mice with A549 xenografts[1]. | Animal Model: | NMRI female nude mice with A549 xenografts[1] | | Dosage: | 3 mg/kg | | Administration: | Intraperitoneal injection; 3 mg/kg, twice a week, for 49 days | | Result: | Reduced tumor volume.
|
| | References | [1] Sheppard, David William, et al. Preparation of heteroaryl compounds as c-MYC mRNA translation modulators and uses thereof in the treatment of cancer. WO2022150316. 2022. |
| | Imidazo[2,1-b]benzothiazole-7-carboxamide, 2-[4-(1-aminocyclopropyl)phenyl]-N-[3-(1-piperidinyl)propyl]- Preparation Products And Raw materials |
|